Fate Therapeutics, Inc. — Form 8-K Summary
Reporting date: September 25, 2026; filed September 28, 2026. This current report concerns a grant award, not a periodic financial-results filing.
Business context and key development
The California Institute for Regenerative Medicine awarded Fate Therapeutics a $15 million grant to support the company’s Phase 2 RECLAIM-LN clinical trial of FT819. The company announced the award in a press release dated September 25, 2026, filed as Exhibit 99.1.
Financial impact and comparison
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures, nor does it quantify the grant’s timing, accounting treatment, or effect on cash runway. No prior-period comparison is provided.
Outlook, risks, and contingencies
The stated use of the grant is to support the Phase 2 trial. The filing provides no additional guidance, trial timeline, grant conditions, milestones, or discussion of risks or contingencies.
Investor facts to verify
- Review Exhibit 99.1 for any additional details about the award and trial.
- Check subsequent filings for grant disbursement timing, conditions, and accounting treatment.
- Monitor company updates for RECLAIM-LN trial progress and any changes to its expected costs or funding needs.